Full Text View
Tabular View
No Study Results Posted
Related Studies
TMC125-C223: TMC125 in HIV-1 Infected Subjects
This study has been completed.
Study NCT00081978   Information provided by Tibotec Pharmaceuticals, Ireland
First Received: April 28, 2004   Last Updated: October 23, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
HIV Infection
Additional conditions recognized in this trial
Acquired Immunodeficiency Syndrome
Communicable Diseases
HIV Infections
Infection
More general conditions related to this trial
Immune System Diseases
Immunologic Deficiency Syndromes
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Sexually Transmitted Diseases
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Virus Diseases
Interventions listed in this trial
TMC125
Additional drug interventions recognized in this trial
Reverse Transcriptase Inhibitors
More general drug interventions related to this trial
Anti-Infective Agents
Anti-Retroviral Agents
Antiviral Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Tibotec Pharmaceuticals, Ireland


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services